Home / Themes / MedTech Long '25: HC Data & Services
MedTech Long '25: HC Data & Services
Last updated
Theme thesis · 3/5 sections · Tickers 1 with notes · 5 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsHospital profitability is rebounding and CMS keeps sweetening value-based and interoperability incentives. Providers racing to cut unit costs and win MA share a
Thesis
Hospital profitability is rebounding and CMS keeps sweetening value-based and interoperability incentives. Providers racing to cut unit costs and win MA share are outsourcing analytics, revenue-cycle and specialty population management to lightweight, cloud-native vendors. Health Catalyst, Veradigm, TruBridge and The Oncology Institute sit at the intersection of AI-driven data liquidity and capitated oncology care, showing double-digit bookings growth, expanding EBITDA margins and growing strategic-buyer interest.
Bull case
AI tailwind: HCAT-Microsoft pact embeds Fabric models in Catalyst's DOS platform, lifting attach rates on tech-enabled managed-services wins.
Regulatory reset: MDRX's 10-K restatement finished; CMS eRx/TEFCA rules reopen data-licensing and transaction-fee growth channels.
Community+oncology leverage: TBRG secures multi-year RCM-EHR deal with Lady of the Sea Hospital; TOI expanding MA bundles as 2025 rate bump boosts per-episode revenue.
Bear case
Macro squeeze: hospital labor inflation, higher rates and stalled elective volumes curb IT budgets despite promised ROI
Compliance drag: SEC scrutiny of MDRX plus new FTC data-broker rules crimp high-margin data-sales growth
VC-funded disruptors bundle AI RCM + ambient EHR for pennies, undercutting TBRG/HCAT legacy footprints
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| MA Oncology Episode PMPM (Per Member Per Month) Cost Trend | Quarterly | Measures TOI's ability to scale value-based oncology care and capitalize on MA rate increases. | Google_Sheets |
| Rural hospital operating margin index | Semi-annual | Gauges financial health of rural hospitals, a key segment for TruBridge's RCM and EHR offerings. | Google_Sheets |
| Net new SaaS & data-licensing bookings for HCAT and MDRX | Quarterly | Indicates growth momentum, cross-sell effectiveness, and expansion of cloud-native solutions. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| TOI_1f5eda90 | In 2026 | 2026-01-01 | 2026-12-31 | TOI targets free cash flow positive in 2026 as it scales operations and benefits from AI-enabled efficiencies and growing capitated revenue. | Key cash-flow milestone potentially enabling debt reduction, reinvestment, and valuation upgrade. | Ticker | 2025-11-13 | earnings_transcript | TOI (ticker) |
| TOI_8d2c1227 | full year positive adjusted EBITDA in 2026 | 2026-01-01 | 2026-12-31 | Achievement of full year positive adjusted EBITDA for 2026. | This is a key financial milestone indicating sustainable profitability and will significantly impact investor sentiment and valuation. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
| TOI_06d1356f | continue expansion across the state in 2026, which would more than double the current partnership. | 2026-01-01 | 2026-12-31 | Expansion of the delegated capitation partnership with Elevance in Florida, aiming to more than double the current partnership in 2026. | This expansion is a significant driver of capitated revenue growth and validates the success of TOI's delegated model, impacting top-line growth and market penetration. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
| TOI_5704e912 | over 80% growth in capitated revenue for the year | 2026-01-01 | 2026-12-31 | Achieving over 80% growth in capitated revenue for the full year 2026. | This is a core growth driver for TOI's value-based care model, directly impacting revenue, profitability, and investor confidence in the company's strategic direction. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
| TOI_d7b60b8a | launch a proprietary new network portal in Q2 | 2026-04-01 | 2026-06-30 | Launch of a proprietary new network portal in Q2 2026. | This portal is expected to improve provider engagement, utilization management, formulary adherence, and drive ancillary services engagement, potentially improving MLR and incremental growth. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
| TOI_0aa47467 | For full year 2026 | 2026-01-01 | 2026-12-31 | Achievement of full year 2026 financial guidance: revenue ($630M-$650M), capitated revenue (~$150M), gross profit ($97M-$107M), and adjusted EBITDA ($0M-$9M). | Meeting or exceeding this guidance is crucial for investor confidence, validating the company's growth strategy and path to profitability, directly impacting valuation. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
| TOI_4b0698eb | in 2026 | 2026-01-01 | 2026-12-31 | Realization of approximately $2 million in SG&A savings from AI-related efficiencies across prior authorization, call center, and RCM in 2026. | Achieving these savings demonstrates the successful implementation and scaling of AI, contributing to margin expansion and operational leverage, which is a key bull point for the company. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
| TOI_a9d546cc | Exiting and second half of the year [2026] | 2026-07-01 | 2026-12-31 | Achieving free cash flow positivity by the end of 2026. | This is a critical financial milestone demonstrating the company's ability to generate cash from operations, reducing reliance on external financing and significantly boosting investor confidence. | Ticker | 2026-03-12 | earnings_transcript | TOI (ticker) |
Constituents
- TOIT2— The Oncology Institute, Inc.
- BTSGT3· no notes yet
- HCATT3· no notes yet
- MDRXT3· no notes yet
- RDNTT3· no notes yet
- TBRGT3· no notes yet